CliffBio
small molecule

ULTANE

SEVOFLURANE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameULTANE
Active ingredientSEVOFLURANE
Strength100%
Dosage formLIQUID
RouteINHALATION
ModalitySmall molecule
FDA approvalJune 1995
Marketing statusRX

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ULTANE patent cliff — loss of exclusivity — | CliffBio